TTC Oncology LLC

Founded in 2015 as an R&D, pre-revenue startup, TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy associated with modulation and mimicry of estrogen actions. Investigators completed Phase I trials on TTC drug at four sites and established drug safety. International phase II clinical trials are in preparation.

Our Clinical Studies Team

Co-Founders of TTC-352 and TTC Oncology Directors

 

TTC Oncology’s Chief Executive and Chief Medical Officer:

Arkadiusz Dudek MD Ph.D.

Professor of medicine at University of Minnesota; medical oncologist at HealthPartners Regions Hospital in St. Paul, MN.

He has more than 20 years’ experience in cancer clinical research, 22 years in clinical management of cancer, and 15 years in tumor biology, signal transduction, and cancer immunotherapy. His expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has served 16 years in leadership positions in clinical trial offices at the University of Minnesota and University of Illinois. He chairs and manages a broad range of therapeutic or non-therapeutic clinical studies trials (phase 1 through phase 3, cooperative group, investigator-initiated, and industry-sponsored studies). He is author and co-author of more than 125 publications in peer-reviewed medical and research journals.

 

Chief Scientific Officer:

Debra A. Tonetti, Ph.D.

Professor of Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago; a breast cancer researcher for 25 years. Trained in the lab of Dr. V.C. Jordan (“Father of Tamoxifen”). Her lab focuses on the etiology and treatment of breast cancer, specifically on mechanisms of endocrine resistance. Her lab was the first to identify PKCα as a biomarker for tamoxifen resistance and developed preclinical xenograft models indicating PKCα is a predictive biomarker for estradiol-induced tumor regression. With Dr. Greg Thatcher, her lab developed the ShERPA, TTC-352, as a safer alternative to estradiol as characterized by a lack of uterine proliferation. She serves as the Chief Scientific Officer for TTC Oncology.

Chief Technical Officer:

Gregory Thatcher, Ph.D.

Hans Vahlteich Chair, Professor of Medicinal Chemistry, and co-leader of Translational Oncology and co-director of the NIA Predoctoral Training Program in Alzheimer’s Disease & Related Dementia, at U of Illinois Chicago; awarded Graduate Mentor and Innovator of the Year; completed SERC Research Fellowship at Oxford University. Over 140 scientific publications and has supervised more than 50 graduate students in chemical biology, chemical toxicology, and medicinal chemistry; research continuously funded by NIH since 2003.
Founded a start-up that took an Alzheimer’s drugs into clinical trials and sold for $35mm. Successfully translated academic drug discovery into investigational new drugs, with two new chemical entities currently in clinical trials for the treatment of metastatic breast cancer.

 

TTC Management

Melody A. Pekarek

General Manager, responsible for overseeing and supporting work performed in the lab through clinical trials, for developing budgets and managing expenses, and for ensuring compliance of all development timelines.  She coordinates with TTC’s angel investor in Arizona.  

 

©2018 by TTC Oncology.